其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Propylene Oxide CAS Registry Number: 75-56-9 环氧丙烷

CAS Name: Methyloxirane
Additional Names: propene oxide
Percent Composition: C 62.04%, H 10.41%, O 27.55%
Literature References: Results from the action of KOH (aq) on propylene chlorohydrin. Toxicity: H. F. Smyth et al., J. Ind. Hyg. Toxicol. 23, 259 (1941). Toxicological comparison with ethylene oxide, q.v.: E. Agurell et al., Mutat. Res. 250, 229 (1991). Reviews: Holden in Glycols, G. O. Curme, F. Johnston, Eds. (Reinhold, New York, 1952) pp 250-261; Faith, Keyes Clark's Industrial Chemicals, F. A. Lowenheim, M. K. Moran, Eds. (Wiley-Interscience, New York, 4th ed., 1975) pp 692-697; R. O. Kirk, T. J. Dempsey in Kirk-Othmer Encyclopedia of Chemical Technology vol. 19 (Wiley-Interscience, New York, 3rd ed., 1982) pp 246-274. Review of manufacturing processes: Chem. Eng. News 70, 9-12 (Mar. 2, 1992); of carcinogenic risk: IARC Monographs 60, 181-213 (1994).

Adapalene CAS Registry Number: 106685-40-9 阿达帕林

CAS Name: 6-(4-Methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid
Additional Names: 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acidTrademarks: Differin (Galderma) Literature References: Retinoid selective for retinoic acid receptor (RAR) subtypes b and g. Prepn: B. Shroot et al., EP 199636; eidem, US 4717720 (1986, 1988 both to Cent. Int. Recher. Dermatol.); and structure-activity study: B. Charpentier et al., J. Med. Chem. 38, 4993 (1995). Pilot-scale synthesis: Z. Liu, J. Xiang, Org. Process Res. Dev. 10, 285 (2006). HPLC determn in plasma and tissue: R. Ruhl, H. Nau, Chromatographia 45, 269 (1997). Clinical pharmacology: C. E. M. Griffiths et al., J. Invest. Dermatol. 101, 325 (1993). Clinical trial in acne: A. Shalita et al., J. Am. Acad. Dermatol. 34, 482 (1996). Reviews of pharmacology and clinical potential: B. A. Bernard, Skin Pharmacol. 6, Suppl. 1, 61-69 (1993); R. N. Brogden, K. L. Goa, Drugs 53, 511-519 (1997); of clinical use in acne vulgaris: J. Waugh et al., Drugs 64, 1465-1478 (2004).

Lamivudine CAS Registry Number: 134678-17-4 拉米夫定

CAS Name: (2R-cis)-4-Amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
Additional Names: (-)-2'-deoxy-3'-thiacytidine; (-)-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cyst...
Literature References: Reverse transcriptase inhibitor. Prepn: J. A. V. Coates et al., WO 9117159 C.A. 117, 111989 (1991). Synthesis of enantiomers: J. W. Beach et al., J. Org. Chem. 57, 2217 (1992); of (-)-enantiomer: D. C. Humber et al., Tetrahedron Lett. 33, 4625 (1992). HPLC determn in urine: D. M. Morris, K. Selinger, J. Pharm. Biomed. Anal. 12, 255 (1994). Clinical trial in hepatitis B: F. Nevens et al., Gastroenterology 113, 1258 (1997). Review of pharmacology and clinical efficacy in HIV infection: C. M. Perry, D. Faulds, Drugs 53, 657-680 (1997).

Emtricitabine CAS Registry Number: 143491-57-0 恩曲他滨

CAS Name: 4-Amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
Additional Names: (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin...
Literature References: Reverse transcriptase inhibitor; nucleoside analog structurally related to lamivudine, q.v. Prepn: D. C. Liotta et al., WO 9214743 (1992 to Emory University); G. Dionne, US 5538975 (1996 to BioChem Pharma, Inc.); L. S. Jeong et al., J. Med. Chem. 36, 181 (1993). Absolute configuration: P. van Roey et al., Antiviral Chem. Chemother. 4, 369 (1993). HPLC-NMR determn of urinary metabolites: J. P. Shockcor et al., Xenobiotica 26, 189 (1996). Comparative efficacy of enantiomers vs HIV: R. F. Schinazi et al., Antimicrob. Agents Chemother. 36, 2423 (1992). Pharmacokinetics: L. W. Frick et al., ibid. 38, 2722 (1994). Mechanism of action study: J. Y. Feng et al., FASEB J. 13, 1511 (1999). Clinical study in combination with didanosine and efavirenz: J.-M. Molina et al., J. Infect. Dis. 182, 599 (2000). Review: P. Cahn, Expert Opin. Invest. Drugs 13, 55-68 (2004).

Huperzine A CAS Registry Number: 102518-79-6 (-)-石杉碱甲

CAS Name: [5R-(5a,9b,11E)]-5-Amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-5,9-methanocycloocta[b]pyridin-2(1H)-one
Additional Names: selagine; HUP
Percent Composition: C 74.35%, H 7.49%,...
Literature References: Reversible alkaloid inhibitor of AChE which crosses the blood-brain barrier. Occurs as the (-)-form in the vegetative part of clubmosses; teas brewed from these mosses have traditionally been used in China to alleviate memory problems. Isolated as selagine from Lycopodium selago L., Lycopodiaceae: J. Muszynski, Q. J. Pharm. Pharmacol. 21, 34 (1948); from Huperzia serrata as huperzine: Chin. Co-op Res. Group, J. Tradit. Chin. Med. 2, 45 (1982). Original structure: Z. Valenta et al., Tetrahedron Lett. 1960, 26; revised structure as huperzine A: J.-S. Liu et al., Can. J. Chem. 64, 837 1986. Identity with selagine: W. A. Ayer et al., ibid. 67, 1538 (1989). Synthesis of (±)-form: A. P. Kozikowski et al., J. Org. Chem. 56, 4636 (1991); G. Campiani et al., ibid. 58, 7660 (1993). NMR spectra: B. N. Zhou et al., Phytochemistry 34, 1425 (1993). HPLC determn in serum: J. Ye et al., J. Chromatogr. B 817, 187 (2005). Anticholinesterase activity: Y.-E. Wang et al., Acta Pharmacol. Sin. 7, 110 (1986); binding profile of enantiomers: M. McKinney et al., Eur. J. Pharmacol. 203, 303 (1991); binding specificity: Y. Ashani et al., Mol. Pharmacol. 45, 555 (1994). Clinical evaluation in senile dementia: R.-W. Zhang et al., Acta Pharmacol. Sin. 12, 259 (1991). Brief review of chemistry and clinical use: D. Bai, Pure Appl. Chem. 65, 1103-1112 (1993).

Lapatinib CAS Registry Number: 231277-92-2 拉帕替尼

CAS Name: N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamineTrademarks: Tykerb (GSK)
Percent Composition: C 59.94%, H 4.51%...
Literature References: Reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Prepn: M. C. Carter et al., WO 9935146 (1999 to Glaxo); eidem, US 6727256 (2004 to SmithKline Beecham). Mechanism of action study: W. Xia et al., Oncogene 21, 6255 (2002); and crystal structure in complex with epidermal growth factor receptor (EGFR, ErbB1): E. R. Wood et al., Cancer Res. 64, 6652 (2004). In vitro antitumor activity in combination with anti-ErbB2 antibodies: W. Xia et al., Oncogene 24, 6213 (2005). Biologic effects on tumor growth: N. L. Spector et al., J. Clin. Oncol. 23, 2502 (2005). Pharmacokinetics and clinical activity in metastatic carcinomas: H. A. Burris III et al., ibid. 5305. Review of clinical development: T. E. Kim, J. R. Murren, IDrugs 6, 886-893 (2003); H. A. Burris III, Oncologist 9, Suppl. 3, 10-15 (2004).

Pyridostigmine Bromide CAS Registry Number: 101-26-8 溴吡斯的明

CAS Name: 3-[[(Dimethylamino)carbonyl]oxy]-1-methylpyridinium bromide
Additional Names: 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate; 1-methyl-3-hydroxypyridinium bromide dimethylcarb...
Literature References: Reversible inhibitor of acetylcholinesterase. Prepn: Urban, US 2572579 (1951 to Hoffmann-La Roche). Mechanism of protective effect in soman poisoning: X. Deyi et al., Fundam. Appl. Toxicol. 1, 217 (1981). Evaluation of effect on neuromuscular function: M. Glikson et al., ibid. 16, 288 (1991). Evaluation of side effects profile under desert conditions: J. E. Cook et al., Mil. Med. 157, 250 (1992). Review of prophylactic effect in nerve agent poisoning: R. M. Dawson, J. Appl. Toxicol. 14, 317 (1994).

Moclobemide CAS Registry Number: 71320-77-9 吗氯贝胺

CAS Name: 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide
Additional Names: p-chloro-N-(2-morpholinoethyl)benzamideTrademarks: Aurorix (Roche); Manerix (Roche); Moclamine (Roche)
Percent Compos...
Literature References: Reversible monoamine oxidase A (MAO-A) inhibitor. Prepn: W. Burkard, P.-C. Wyss, DE 2706179; US 4210754 (1977, 1980 both to Hoffmann-La Roche). Gas chromatography: K. P. Maguire et al., J. Chromatogr. 278, 429 (1983). Human pharmacokinetics: F. A. Wiesel et al., Eur. J. Clin. Pharmacol. 28, 89 (1985). Clinical study: J. K. Larsen et al., Acta Psychiatr. Scand. 70, 254 (1984). Review of pharmacology: W. P. Burkard et al., J. Pharmacol. Exp. Ther. 248, 391-399 (1989); of neurochemical profile: M. DaPrada et al., ibid. 400-414.

Befloxatone CAS Registry Number: 134564-82-2 贝氟沙通

CAS Name: (5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinonePercent Composition: C 51.58%, H 5.19%, F 16.32%, N 4.01%, O 22.90%
Literature References: Reversible monoamine oxidase type A (MAO-A) inhibitor. Prepn: F. X. Jarreau et al., EP 424244; eidem, US 5036091 (1990, 1991 both to Delalande). Pharmacology: D. Caille et al., J. Pharmacol. Exp. Ther. 277, 265 (1996). Biochemical profile: O. Curet et al., ibid. 253. Structure-activity study: J. Wouters et al., Bioorg. Med. Chem. 7, 1683 (1999). Review of clinical pharmacology: P. Rosenzweig et al., J. Affective Disord. 51, 305-312 (1998).

Toloxatone CAS Registry Number: 29218-27-7 涛洛西酮

CAS Name: 5-(Hydroxymethyl)-3-(3-methylphenyl)-2-oxazolidinone
Additional Names: 5-(hydroxymethyl)-3-m-tolyl-2-oxazolidinoneTrademarks: Humoryl (Delalande); Perenum (Delalande)
Percent Compo...
Literature References: Reversible monoamine oxidase type A inhibitor. Prepn: C. Fauran et al., DE 2012120; eidem, US 3655687 (1970, 1972 both to Delalande); eidem, Chim. Ther. 8, 324 (1973). Pharmacology: G. Raynaud et al., ibid. 328. Psychopharmacological profile: J.-P. Kan et al., Eur. J. Med. Chem. 12, 13 (1977); H. Giono-Barber et al., Arzneim.-Forsch. 27, 1188 (1977). Pharmacokinetics: M. S. Benedetti et al., ibid. 32, 276 (1982). Metabolism: A. Malnoe, M. S. Benedetti, Xenobiotica 9, 281 (1979). GLC determn in plasma: S. Vajta et al., J. Chromatogr. 274, 139 (1983). Clinical evaluation in panic disorder: G. Perna et al., J. Clin. Psychopharmacol. 14, 414 (1994).